Agios

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

R&D

3rd to 7th June – This week in clinical trials

In this instalment of our clinical trials round-ups, we look at life sciences research and development announced during the week of 3rd to 7th June, from early-stage onwards.

R&D

This week in clinical trials: 2nd-5th January 2024

Despite the multiple challenges that faced clinical trials in 2023, according to GlobalData’s Pharmaceutical Intelligence Centre, some 22,338

News

Servier’s $1.8bn Agios deal delivers glioma prospect

IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.

News

Servier gets a win for cancer drug Tibsovo, bought in $1.8bn...

Just three months after completing its $1.8 billion takeover of Agios' oncology pipeline, Servier has reported pos

News

Servier beefs up in cancer, buying Agios’ oncology business ...

French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on gen

Agios shares slump on sickle cell disease data

3rd to 7th June – This week in clinical trials

This week in clinical trials: 2nd-5th January 2024

Servier’s $1.8bn Agios deal delivers glioma prospect

Servier gets a win for cancer drug Tibsovo, bought in $1.8bn...

Servier beefs up in cancer, buying Agios’ oncology business ...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Agios

Editor's Picks